BofA raised the firm’s price target on Kymera Therapeutics (KYMR) to $112 from $71 and keeps a Buy rating on the shares after the company reported positive results for its Phase 1b study assessing KT-621 in moderate to severe atopic dermatitis. The firm is “encouraged” by the results, which it thinks supports KT-621 as having a clinical profile similar to dupilumab, but with a more convenient oral administration, believes the drug could expand the AD market if approved, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $116 from $69 at Wells Fargo
- Kymera Therapeutics price target raised to $119 from $70 at Barclays
- Kymera Therapeutics’ KT-621: Promising Market Potential and Competitive Positioning in Atopic Dermatitis Treatment
- Closing Bell Movers: Toll Brothers slips 4% after Q4 earnings miss
- Kymera Therapeutics price target raised to $118 from $70 at Leerink